anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This pretest-posttest randomized controlled experimental study was designed as a randomized controlled parallel designed trial.

This study was conducted at the nursing department of a state university. The population of the study consisted of second-year nursing students who enrolled in the Surgical Nursing course. The study was conducted with students who met the inclusion criteria in the study without any sample calculation. Class size was 100 and 97 of them agreed to participate in the study. The students were assigned to the VBT group or the traditional training group via a stratified randomization method in order to ensure the balance between the groups. The study was carried out with 49 experimental and 48 control groups. After the students were divided into two groups according to gender, an equal number of male and female students were assigned to the experimental and control groups by drawing lots, one of the simple random sampling methods. The student participants were randomly assigned to one of the two groups using a random number table. To avoid bias in this randomized controlled study, assignments to the groups were made by an outside researcher. All training sessions were carried out by researchers. Dependent variables of the research project are; students' level of knowledge, and the independent variables are student information data. Data collection forms (student information, knowledge levels) developed by researchers using the literature

Video scenario: It consisted of a preoperative patient case, learning objectives for nursing care, the content of the scenario and the roles. The scenario involved one 65-year-old female patient who had weight loss, loss of appetite, abdominal pain, and bloating for preoperative preparation of left hemicolectomy surgery. It has been prepared by the formal education given within the scope of the surgical nursing course. The scenario was designed with careful consideration given to conceptual, psychological, and physical realities. The content validity of scenario was assessed by four expert nursing faculty members.

İmplementation: The training was presented to the experimental group by video, and to the control group by the traditional method (using a lecture-style PowerPoint presentation with supporting visual components, question-answer, and narrative method). Before the training, both groups answered the "The Student Information Form" and "The Knowledge Form" and were informed about the purpose of the course, learning objectives and outcomes, and scenario roles, and their questions were answered. The students were informed that their involvement in the research was voluntary and had no bearing on their course grades no academic credit would be given for participating. At the end of the training of both groups, all the scenario was discussed with the students, and their questions were answered. Right after training (post-test 1) and three weeks later (post-test 2: two weeks after post-test 1), the students answered 'The Knowledge Form'.
The invention relates to application of sex hormones in treating rheumatoid arthritis (RA). RA does not have a definite pathogenic factor, and no medicine can treat RA. However, the inventor has found out the pathogenic factor, which is simultaneous partial absence of two hormones on gonadal axis. Besides the known effects, the two hormones have a physiologic moisture retention function for the kidney. When both of the hormones are absent simultaneously, the moisture retention function is degraded, causing decrease of blood volume at the same time and further causing secondary hyperaldosteronism. The secondary hyperaldosteronism enables people to retain sodium and excrete potassium, so that people suffer from myoplegia caused by potassium deficiency and lose the function of a muscular pump, and the far-end venous pressure is enhanced, causing arthroncus. The long-term potassium deficiency initiates hypokalemic nephritis which has the symptoms of diuresis, dehydration and vicious circle of decreased blood volume; at that time, only intense excitement of sympathetic nerves in the three major elements for maintaining blood pressure can maintain the blood pressure; and as a result, the connective tissue capillary vessels intensely constrict, causing hypoxemia, necrosis and inflammations. When the sex hormone (gonadotropic hormone) is used for treating RA, after the kidney moisture retention function of the sex hormone recovers, no subsequent serial symptoms of RA occur.
An 11-year old, intact male Border Collie was referred with a history of subacute and progressive left eye exophthalmos and mydriasis associated with reduced pupillary light reflex, ventrolateral strabismus, and absence of physiologic nystagmus in the left eye. Neuroanatomical localization was consistent with a left oculomotor neuropathy, involving the general somatic and visceral parasympathetic efferent components. Computed tomography and magnetic resonance imaging of the head were performed. Imaging findings were consistent with an infectious-inflammatory process involving the left retrobulbar space and regional muscles, extending intracranially through the left orbital fissure. Cerebrospinal fluid (CSF) was collected from the cerebellomedullary cistern, and the analysis revealed albuminocytologic dissociation. The dog was treated with amoxicillin and clavulanic acid and prednisolone at anti-inflammatory dose; a significant improvement of neurologic status was observed afterward. However, 4 weeks after the initial presentation, the dog showed an abnormal, bilateral adduction of both eyes and third eyelid protrusion of the left eye while chewing the leash; the dog's mental status was normal, and the patient did not appear to be in discomfort during these episodes. A presumptive diagnosis of acquired trigemino-oculomotor synkinesis, induced by the intracranial inflammation was made. To the authors' best knowledge, this is the first case of presumed trigemino-oculomotor synkinesis reported in veterinary medicine.
OBJECTIVE: To investigate the association between meteorological data three days before admission and the status of sputum pathogens culture in hospitalized patients with Acute exacerbation of Chronic obstructive pulmonary disease (AECOPD) and respiratory infections.
METHODS: Data from 1,370 AECOPD patients (80.66% males, approximately 80% age > 70) with respiratory infections hospitalized in Fujian Provincial Hospital between December 2013 and December 2019 were collected. This cohort comprised, along with concurrent meteorological data from Fuzhou. Group differences were analyzed to compare the meteorological data three days prior to admission between patients with positive sputum pathogen cultures and those without. Logistic regression models were employed to investigate the association between meteorological parameters and the status of sputum pathogen cultures in patients with AECOPD and respiratory infections. Sensitivity analyses was conducted among the hospitalized patients from 2013 to 2016 and 2017-2019. Stratified analysis was performed to explore the factors affecting the effect of temperature differences and their interactions.
RESULTS: 578(42.19%) cases had a positive sputum culture report indicating pathogen growth. 323 cases were found with Gram-negative bacteria, 160 with Gram-positive bacteria, and 114 with fungi. Uni-variate analysis revealed statistical differences in DTD three days prior to admission (DTD-3d) between the positive and negative sputum culture groups (p = 0.019). Multivariate analysis indicated that an increase in the risk of positive sputum pathogen cultures was associated with greater DTD three days before admission (DTD-3d), with OR1.657 (95%CI [ 1.328-1.981]). The risk of positive sputum pathogen cultures was higher in groups with greater DTD-3d. The findings were consistent across different admission periods. Stratified analysis showed that patients without respiratory failure were more affected by DTD-3d, and an interaction effect was observed (p < 0.001).
CONCLUSION: In coastal areas, the diurnal temperature difference three days prior to admission affects the sputum pathogen status in AECOPD patients with respiratory infections.
Prograf can cause neurotoxicity, particularly when used in high doses. Neurotoxicity, including tremor, headache, and other changes in motor function, mental status, and sensory function were reported in approximately 55% of liver transplant recipients in the two randomized studies. Tremor occurred more often in Prograf-treated kidney transplant patients (54%) and heart transplant patients (15%) compared to cyclosporine-treated patients. The incidence of other neurological events in kidney transplant and heart transplant patients was similar in the two treatment groups (see ADVERSE REACTIONS). Tremor and headache have been associated with high whole-blood concentrations of tacrolimus and may respond to dosage adjustment. Seizures have occurred in adult and pediatric patients receiving Prograf (see ADVERSE REACTIONS). Coma and delirium also have been associated with high plasma concentrations of tacrolimus. 

Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES). Symptoms indicating PRES include headache, altered mental status, seizures, visual disturbances and hypertension. Diagnosis may be confirmed by radiological procedure. If PRES is suspected or diagnosed, blood pressure control should be maintained and immediate reduction of immunosuppression is advised. This syndrome is characterized by reversal of symptoms upon reduction or discontinuation of immunosuppression.
Bacteria in the human body, particularly in the large intestine, are known to be associated with various diseases. To identify disease-associated bacteria (markers), a typical method is to statistically compare the relative abundance of bacteria between healthy subjects and diseased patients. However, since bacteria do not necessarily cause diseases in isolation, it is also important to focus on the interactions and relationships among bacteria when examining their association with diseases. In fact, although there are common approaches to represent and analyze bacterial interaction relationships as networks, there are limited methods to find bacteria associated with diseases through network-driven analysis. In this paper, we focus on rewiring of the bacterial network and propose a new method for quantifying the rewiring. We then apply the proposed method to a group of colorectal cancer patients. We show that it can identify and detect bacteria that cannot be detected by conventional methods such as abundance comparison. Furthermore, the proposed method is implemented as a general-purpose tool and made available to the general public.
As with other agents administered either intravenously or intramuscularly, careful supervision of dose and rate of injection should be observed. Rate of injection should not exceed 3 mL per minute-i.e., one 10 mL vial in approximately three minutes. Since Methocarbamol Injection is hypertonic, vascular extravasation must be avoided. A recumbent position will reduce the likelihood of side reactions. 

Blood aspirated into the syringe does not mix with the hypertonic solution. This phenomenon occurs with many other intravenous preparations. The blood may be injected with the methocarbamol, or the injection may be stopped when the plunger reaches the blood, whichever the physician prefers. 

The total dosage should not exceed 30 mL (three vials) a day for more than three consecutive days except in the treatment of tetanus. 

Caution should be observed in using the injectable form in patients with suspected or known seizure disorders.

Information for Patients

Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.  Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.
BACKGROUND: Recent studies identify large quantities of inflammatory cellular debris within Fresh Frozen Plasma (FFP). As FFP is a mainstay of hemorrhagic shock resuscitation, we used a porcine model of hemorrhagic shock and ischemia/reperfusion to investigate the inflammatory potential of plasma-derived cellular debris administered during resuscitation.
METHODS: The porcine model of hemorrhagic shock included laparotomy with 35 % hemorrhage (Hem), 45 min of ischemia from supraceliac aortic occlusion with subsequent clamp release (IR), followed by protocolized resuscitation for 6 h. Cellular debris (Debris) was added to the resuscitation phase in three groups. The four groups consisted of Hem + IR (n = 4), Hem + IR + Debris (n = 3), Hem + Debris (n = 3), and IR + Debris (n = 3). A battery of laboratory, physiologic, cytokine, and outcome data were compared between groups.
RESULTS: As expected, the Hem + IR group showed severe time dependent decrements in organ function and physiologic parameters. All animals that included both IR and Debris (Hem + IR + Debris or IR + Debris) died prior to the six-hour end point, while all animals in the Hem + IR and Hem + Debris survived. Cytokines measured at 30-60 min after initiation of resuscitation revealed significant differences in IL-18 and IL-1β between all groups.
CONCLUSIONS: Ischemia and reperfusion appear to prime the immune system to the deleterious effects of plasma-derived cellular debris. In the presence of ischemia and reperfusion, this model showed the equivalency of 100 % lethality when resuscitation included quantities of cellular debris at levels routinely administered to trauma patients during transfusion of FFP. A deeper understanding of the immunobiology of FFP-derived cellular debris is critical to optimize resuscitation for hemorrhagic shock.
Participants in this arm will participate in an 8-week bikeshare training program, using Indego, the bike sharing service in Philadelphia. The first sessions will be aimed at increasing knowledge of the bike share program and the procedures for utilizing it successfully. Then participants will meet with a peer support specialist, who will help facilitate individualized route planning and independent ride support. Peer support specialists will use motivational interviewing during these individual sessions in order to help participants identify personally meaningful motivations for participation and to enhance their sense of self-efficacy.
SITA at a daily oral dose of 100 mg. The participants randomized to this group will receive 1 tablet daily of SITA 100 mg + 1 tablet of EVO placebo for 12 weeks.
Atrial fibrillation (AF) is a prevalent clinical arrhythmia disease and is an important cause of stroke, heart failure, and sudden death. Due to the insidious onset and no obvious clinical symptoms of AF, the status of AF diagnosis and treatment is not optimal. Early AF screening or detection is essential. Internet of Things (IoT) and artificial intelligence (AI) technologies have driven the development of wearable electrocardiograph (ECG) devices used for health monitoring, which are an effective means of AF detection. The main challenges of AF analysis using ambulatory ECG include ECG signal quality assessment to select available ECG, the robust and accurate detection of QRS complex waves to monitor heart rate, and AF identification under the interference of abnormal ECG rhythm. Through ambulatory ECG measurement and intelligent detection technology, the probability of postoperative recurrence of AF can be reduced, and personalized treatment and management of patients with AF can be realized. This work describes the status of AF monitoring technology in terms of devices, algorithms, clinical applications, and future directions.
BACKGROUND: The neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) has emerged as a promising biomarker for assessing inflammation and lipid dysregulation. Increasing evidence indicates that these metabolic disturbances play a crucial role in the development of metabolic dysfunction-associated steatotic liver disease(MASLD). This study aims to investigate the association between NHR, MASLD, and liver fibrosis.
METHODS: This cross-sectional study analyzed data from the 2017-2020 National Health and Nutrition Examination Survey (NHANES). Weighted multivariate logistic regression models were used to investigate the association between NHR and both MASLD and liver fibrosis. Smoothed curve fitting and threshold effect analysis were performed to detect potential nonlinear relationships. Subgroup analyses were conducted to assess the consistency of these associations across different groups.
RESULTS: The study involved 4,761 participants. We observed a significant positive association between NHR and MASLD (OR = 1.20, 95% CI: 1.09-1.31). However, there was no significant association between NHR and liver fibrosis (OR = 1.01; 95% CI: 0.94-1.09). The analysis of smoothed curve fitting and threshold effect revealed an inverted U-shaped relationship between NHR and MASLD, with a turning point at 5.63.
CONCLUSION: Our findings indicate a positive correlation between elevated NHR levels and MASLD prevalence. However, we did not observe a significant association between NHR and liver fibrosis prevalence. Further prospective research is needed to validate these findings in a longitudinal setting.
The invention relates to a dihydroporphin photosensitizer as well as a preparation method and an application thereof. The dihydroporphin photosensitizer is meso-4(3-N,N-diethylaminemethyl)-4-metoxyphenyl)-dihydroporphin, and the chemical structural formula thereof is provided. The photosensitizer is prepared by the following steps: reducing meso-4(3-N,N-diethylaminemethyl)-4-metoxyphenyl)-dihydroporphin through a reducer in the presence of nitrogen gas and eluting through silica gel column chromatography. The dihydroporphin photosensitizer provided by the invention is used for preparing medicines for treating tumors and photoactivated insecticides. The preparation method is simple. The dihydroporphin photosensitizer can be made into hydrochloride injections to use, and has wide application prospects.
PURPOSE: The usability of a new surgical navigation system that provides patient-specific vascular information for robotic gastrectomy in gastric cancer remains unexplored for laparoscopic gastrectomy owing to differences in surgical environments. This study aimed to evaluate the applicability and safety of this navigation system in laparoscopic gastrectomy and to compare the post-operative outcomes between procedures with and without its use.
MATERIALS AND METHODS: Between June 2022 and July 2023, 38 patients across 2 institutions underwent laparoscopic gastrectomy using a navigation system (navigation group). The technical feasibility, safety, and accuracy of detecting variations in vascular anatomy were measured. The perioperative outcomes were compared with 114 patients who underwent laparoscopic gastrectomy without a navigation system (non-navigation group) using 1:3 propensity score matching during the same study period.
RESULTS: In all patients in the navigation group, no adverse events associated with the navigation system occurred during surgery in any patient in the navigation group. No accidental vessel injuries necessitate auxiliary procedures. All vessels encountered during the gastrectomy were successfully reconstructed and visualized. Patient demographics and operative data were comparable between the 2 groups. The navigation group exhibited a significantly lower overall complication rate (10.5%) than the non-navigation group (26.3%, P=0.043). Notably, pancreas-related complications were absent in the navigation group but occurred in eight cases in the non-navigation group (7.0%, P=0.093), although the difference was not statistically significant.
CONCLUSIONS: The patient-specific surgical navigation system demonstrated clinical feasibility and safety for laparoscopic gastrectomy for gastric cancer, potentially reducing complication rates compared with laparoscopic gastrectomy without its use.
In a previous 6-month study in patients with both vascular dementia and Alzheimer's dementia, galantamine demonstrated positive results on thinking, functioning, behavior, speech and overall well being of patients, and prevented the behavior symptoms of dementia from appearing. This combined study consists of two almost identical 26-week studies that examine the same criteria as the previous study, but in a larger patient population (dementia has been identified as having been caused by blood vessel disease without Alzheimer's disease). The study starts with a 4-week period in which current medications for dementia are withdrawn followed by a 26-week double-blind treatment period when patients will receive either placebo or galantamine 8 milligrams or 12 milligrams twice a day. Effectiveness will be measured by changes in scores on the Alzheimer's Disease Assessment Scale cognitive subscale, Alzheimer's Disease Cooperative Study Scale, the Clinician's Interview-Based Impression of Change Plus, and the neuropsychiatric inventory, as well as (in English-speaking countries only) a 10-minute interview of the patient (EXIT-25 scale). Safety will be evaluated throughout the study based on the incidence and severity of unexpected events, laboratory and physical tests, and vital signs. The hypothesis of the study is that galantamine will improve thinking, function, behavior, speech, and overall well being, better than placebo. A voluntary pharmacogenomic study will be incorporated into the study plan to evaluate whether specific genes are related to the dementia or drug response. 8 milligrams (mg) 2 times a day for 8 weeks, then increasing to12 mg, if tolerated. After 12 weeks dose can be reduced to 8 mg or matching placebo
1\. Load filtered blood and remaining bags into centrifuge cup, ensuring that the tubing stays in the top half of the cup.

2\. Centrifuge at appropriate conditions to produce desired components.

3\. Carefully remove the unit from the centrifuge and place the red cell storage bag in the plasma expressor.

4\. Clamp tubing to extra satellite bags, if present.

5\. Gently apply expressor pressure.

6\. Open snap-open closure to satellite bag and express plasma.

7\. After plasma is expressed, clamp tubing between red cell storage bag and Y connector, and release expressor pressure.

8\. Clamp tubing between the Y connector and plasma bag.

9\. Hang AS-3 bag above red cell storage bag and remove clamp from tubing to the red cell storage bag.

10\. Open snap-open closure on the bag containing the AS-3 additive solution and transfer to the bag containing the red cells. Note: AS-3 solution should be added to the packed red blood cells immediately after removal of plasma. Transfer AS-3 solution under one of the following processing conditions:

a. within 8 hours of collection if whole blood is held at room temperature.

b. within 72 hours of collection if whole blood is refrigerated.

11\. Seal tubing and detach the bag containing packed red cells, and set aside plasma for further processing.** Note: If quality control is to be performed on postfiltration sample, leave an adequate length (~10 inches) of tubing attached to the bag containing red cells.

12\. Gently mix packed red cells and AS-3 solution.

13\. Store CP2D/AS-3 preserved red blood cells at 1—6 °C for up to 42 days and use as indicated. Note: If AS-3 is not used, whole blood or red blood cells in CP2D alone may be stored at 1—6 °C for up to 21 days.